1 pahu (10 Vials)
| Loaʻa: | |
|---|---|
| Ka nui: | |
▎ He aha ka FOXO4-DRI?
ʻO ka inoa piha o FOXO4-DRI ʻo FOXO4 D-Retro-Inverso. He polypeptide anti-kahiko ia e hoʻoulu i ka apoptosis o nā cell senescent ma ke kāohi ʻana i ka pilina ma waena o FOXO4 a me p53, a laila e hoʻomaikaʻi ai i ka microenvironment tissue a hoʻopaneʻe i ke kaʻina hana ʻelemakule.
▎ Hoʻolālā FOXO4-DRI
Puna: PubChem |
Sequence: LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRG Hui Molekala: C 228H 388N 86O64 Kaumaha Molekala: 5358g/mol PubChem CID: 168431240 Nā huaʻōlelo like: EX-A7431 |
▎ FOXO4-DRI Research
He aha ke kumu noiʻi o FOXO4-DRI?
Noiʻi hohonu e pili ana i ka Senescence Cellular:
Me ka hoʻomau ʻana i ka noiʻi hohonu o ke ʻano o ka senescence cellular, ua ʻike ʻia he kuleana koʻikoʻi ka senescence cellular i nā kaʻina hana physiological a me ka hanana a me ka ulu ʻana o nā maʻi. E hōʻiliʻili a hūnā nā cell Senescent i nā ʻano cytokines a me nā mediators inflammatory, e hoʻopili ana i nā hana o nā cell a puni, a pēlā e alakaʻi ai i ka emi ʻana o ka hana o ke kino a me ke kino. No laila, ʻo ka ʻimi ʻana i nā ʻano e komo ai i ke kaʻina hana o ka senescence cellular ua lilo i wahi wela noiʻi.
ʻIke ʻia o FOXO4 Protein:
He lālā ʻo FOXO4 o ka pahu forkhead box protein O family (FOXO) a he kuleana koʻikoʻi i loko o nā kaʻina olaola like ʻole e like me ka ulu ʻana o nā cell, ka ʻokoʻa, ka apoptosis, a me ka pane ʻana i ke kaumaha. Ua ʻike nā haʻawina he pili pili loa ʻo FOXO4 i ke ʻano o ka cellular senescence, a hiki iā ia ke hoʻopilikia i ke kaʻina hana o ka senescence o nā cell ma o ka hoʻoponopono ʻana i ka hōʻike ʻana o ke ʻano o nā genes. No ka laʻana, hiki i ka FOXO4 ke hoʻoikaika i ka hōʻike ʻana o kekahi mau genes antioxidant a me nā genes repair DNA, e hoʻonui ai i ke kūʻē ʻana o ke kelepona i ke koʻikoʻi oxidative a me ka pōʻino DNA, a laila e hoʻopaneʻe ana i ka senescence cellular.
ʻO ka nānā ʻana o nā huila liʻiliʻi liʻiliʻi:
Ma muli o ka hoʻomaopopo ʻana i ka hana o ka protein FOXO4, ua hoʻomaka ka poʻe ʻepekema e nānā i nā pūhui mole liʻiliʻi e hiki ke hoʻoponopono i ka hana o FOXO4. Manaʻolana lākou e loaʻa i kahi mea mole liʻiliʻi e hiki ke hoʻoikaika pono i ka protein FOXO4, pēlā e hoʻohana ai i kāna hopena anti-aging a mālama i nā maʻi pili. Ma hope o ka nui o nā hōʻike hoʻokolohua a me nā loiloi, ua ʻike hope ʻia ka pūhui mole liʻiliʻi FOXO4-DRI. Hiki iā ia ke hoʻopaʻa pono i ka protein FOXO4, hoʻāla i kāna ala hōʻailona i lalo, a pāʻani i kahi kuleana i ka hoʻoponopono ʻana i ka senescence cellular a me nā hana physiological pili.
He aha ke ʻano o ka hana a FOXO4-DRI?
1. Anti-kahiko
Hiki i ka FOXO4-DRI ke hoʻoikaika i ka protein FOXO4, a laila hoʻoponopono i ka metabolism o ka cell, proliferation, a me nā kaʻina apoptosis. He kuleana koʻikoʻi ka protein FOXO4 i nā cell. Hiki iā ia ke hoʻoikaika i ke kūʻē ʻana o ke kelepona i ke koʻikoʻi ma o ka hoʻoponopono ʻana i ka hōʻike ʻana o ke ʻano o nā genes i lalo, a e hōʻemi i ka senescence a me ka pōʻino. Eia kekahi laʻana, hiki i ka FOXO4 ke hoʻoikaika i ka'ōlelo o nā enzymes antioxidant a ho'ēmi i ke kiʻekiʻe o nāʻano oxygen reactive intracellular, pēlā e hoʻohaʻahaʻa ai i ka pōʻino o ke koʻikoʻi oxidative i nā pūnaewele [1, 2] . Eia kekahi, hiki i ka FOXO4 ke hoʻoponopono i ka hōʻike o nā genes e pili ana i ka pōʻai cell, ke kāohi i ka hoʻonui nui o ka cell, a mālama i ka metabolism maʻamau a me ka hana o nā cell.
2. Mechanism of Action in Male Late-Onset Hypogonadism
Ka pilina me FOXO4 a me p53:
ʻO ka hypogonadism male hope loa he maʻi e pili ana i ka makahiki, a ʻo kāna ʻano kumu ʻo ia ka hana ʻole o nā pūnaewele Leydig senescent i loko o ka hōʻike. Ua ʻike ʻia ʻo ka pahu forkhead box O (FOXO) transcription factor FOXO4 i hōʻike ʻia i loko o nā keena Leydig kanaka, a ʻo kona unuhi ʻana i ka nucleus i ka poʻe ʻelemakule e pili ana i ka emi ʻana o ka synthesis testosterone. Ma keʻano he FOXO4 blocker, FOXO4-DRI koho koho i ka p53 nuklea hoʻokuʻu a me ka apoptosis i nā pūnaewele Leydig senescent ma o ka hoʻopauʻana i ka pilina ma waena o FOXO4 a me p53 [1].
Hoʻomaikaʻi i ka Microenvironment Testicular:
I nā ʻiole kahiko maoli, hiki i ka FOXO4-DRI ke hoʻomaikaʻi i ka microenvironment testicular a hoʻēmi i ka nele o ka testosterone pili makahiki. Hōʻike kēia e hiki i ka FOXO4-DRI ke hoʻihoʻi i ka hana maʻamau o ka ʻiʻo testicular ma ka hoʻoponopono ʻana i ke ala hōʻailona e pili ana i ka senescence o nā cell Leydig, a laila e hoʻonui ai i ka pae huna testosterone [1].
3. Mechanism of Action in Pulmonary Fibrosis
E ho'ēmi ana i nā pūnaewele Senescent a me ka hoʻohaʻahaʻaʻana i ka'ōlelo SASP:
ʻO ka pulmonary fibrosis kahi maʻi māmā interstitial holomua me nā koho lapaʻau liʻiliʻi. Ua manaʻo ʻia ka senescence kelepona kekahi o nā kumu pathogenic o ka pulmonary fibrosis, a ʻo ka hoʻopau ʻia ʻana o nā cell senescent hiki ke hoʻomaikaʻi i ka hana o ka māmā. I loko o kahi kiʻi ʻiole o ka pulmonary fibrosis i hoʻoulu ʻia e bleomycin, FOXO4-DRI, e like me ka pirfenidone lāʻau i ʻae ʻia, hiki ke hōʻemi i nā cell senescent, hoʻohaʻahaʻa i ka hōʻike ʻana o ka senescence-associated secretory phenotype (SASP), a hoʻohaʻahaʻa i nā loli morphological a me ka deposition collagen i hoʻokomo ʻia e bleomycin ..
Ke hoʻololi nei i ka ʻāpana o nā ʻano kelepona:
Hiki i ka FOXO4-DRI ke hoʻonui i ka hapa o ke ʻano 2 alveolar epithelial cell (AEC2) a me nā fibroblasts a hoʻemi i ka nui o nā myofibroblasts i loko o kahi kiʻi kiʻi o ka pulmonary fibrosis i hoʻoulu ʻia e bleomycin. I loko o nā hoʻokolohua in vitro, i hoʻohālikelike ʻia me ka ʻiole a me nā laina kelepona fibroblast lung kanaka, ʻoi aku ka manaʻo o FOXO4-DRI e pepehi i nā myofibroblasts i hoʻoulu ʻia e ka hoʻololi ʻana i ka mea ulu-β (TGF-β) [2].
Hoʻoponopono ʻana i ke ala e pili ana i ka Extracellular Matrix Receptor Interaction:
ʻO ka hopena paʻa o FOXO4-DRI ma nā myofibroblasts e alakaʻi i ka hoʻohaʻahaʻa ʻana o ka extracellular matrix (ECM) alahele hoʻokipa receptor i ka bleomycin-induced pulmonary fibrosis. Hōʻike kēia e hiki i ka FOXO4-DRI ke hoʻomaikaʻi i ke kaʻina hana pathological o ka pulmonary fibrosis ma o ka hoʻoponopono ʻana i ka hanauna a me ka metabolism o ka ECM [2].

Hoʻomaikaʻi ʻo FOXO4-DRI i ka bleomycin (BLM) -induced pulmonary fibrosis (PF). (A) Kiʻikuhi kiʻi e hōʻike ana i ka hoʻolālā hoʻokolohua. (B) Nā kiʻi i nānā ʻia e nā lunamakaʻāinana o ka haematoxylin-eosin (HE) a me Masson trichrome-staining o nā ʻāpana ʻiʻo māmā.
Puna:PubMed [2]
He aha nā mea hoʻohana o FOXO4-DRI?
1. Anti-kahiko
Loaʻa ka waiwai o FOXO4-DRI i ka hoʻomaikaʻi ʻana i ka emi ʻana o ka hana pili makahiki. Me ka piʻi ʻana o ka makahiki, e ʻike nā ʻāpana like ʻole a me nā ʻōnaehana o ke kino i nā pae like ʻole o ka ʻelemakule a me ka emi ʻana o ka hana, e like me ka emi ʻana o ka hana o ka ʻōnaehana pale, ka nāwaliwali o ka ʻōnaehana cardiovascular, a me ka emi ʻana o ka hana ʻōnaehana nerve. Ma ka hoʻoulu ʻana i ka protein FOXO4, hiki i ka FOXO4-DRI ke hoʻopaneʻe i ke kaʻina hana o ka senescence cellular, hoʻomaikaʻi i ka ikaika o ka cell a me ka hana, a pēlā e kōkua ai i ka hoʻomaikaʻi ʻana i ke olakino holoʻokoʻa o ke kino. No ka laʻana, i loko o kahi kiʻi ʻiole kahiko, hiki i ka mālama ʻana me FOXO4-DRI ke hoʻomaikaʻi nui i ka hiki ke hoʻoikaika kino a me ka hana cognitive o nā ʻiole a hoʻemi i ka loaʻa ʻana o nā maʻi pili makahiki [1, 2].
2. Lapaau i na ma'i Neurodegenerative
Ka pilina me Neuron Aging and Death:
ʻO nā maʻi neurodegenerative e like me ka maʻi Alzheimer a me ka maʻi Parkinson e pili kokoke ana i ka ʻelemakule a me ka make o nā neurons. I kēia mau maʻi, e hōʻino ʻia nā neurons e nā ʻano like ʻole e like me ke koʻikoʻi oxidative, pane inflammatory, a me ka hōʻuluʻulu protein, e alakaʻi ana i ka nalowale ʻana o ka hana neuronal a i ka hopena e hoʻopilikia ai i ka cognitive a me ka hana kaʻa. Ma ka ho'ālaʻana i ke ala hōʻailona FOXO4, hiki i ka FOXO4-DRI ke hoʻoikaika i ke ola a me ka hoʻoponoponoʻana o nā neurons a hoʻonui i ko lākou kū'ēʻana i ke kaumaha oxidative a me nā hōʻailona apoptotic.
Hiki i ka protein FOXO4 ke hoʻoponopono i ka hōʻikeʻana o nā genes he nui i loko o nā neurons, me nā enzymes antioxidant, nā protein anti-apoptotic, nā kumu ulu o ke aʻalolo, a me nā mea'ē aʻe. No ka laʻana, ma kahi hoʻohālike ʻiole o ka maʻi o Alzheimer, hiki i ka mālama ʻana me FOXO4-DRI ke hōʻemi i ka waiho ʻana o nā protein amyloid, hoʻomaikaʻi i ka hana neuronal, a hoʻolohi i ka piʻi ʻana o ka maʻi. I loko o kahi hiʻohiʻona maʻi o Parkinson, hiki i ka FOXO4-DRI ke pale i nā neurons dopaminergic a hoʻomaikaʻi i ka hoʻoikaika kino o nā ʻiole [3, 4] . No laila, manaʻo ʻia e hoʻohana ʻia ʻo FOXO4-DRI i ka mālama ʻana i nā maʻi neurodegenerative e hoʻolōʻihi i ka piʻi ʻana o ka maʻi a hoʻomaikaʻi i nā hana cognitive a me nā kaʻa o nā maʻi.
3. Kāohi a me ka mālama ʻana i nā maʻi maʻi cardiovascular
Ka pale ʻana i nā Cardiomyocytes:
I ka ʻōnaehana cardiovascular, hiki i ka FOXO4-DRI ke pale i nā cardiomyocytes mai ke kaumaha oxidative a me ka pōʻino apoptotic. ʻO nā Cardiomyocytes nā pūnaewele hana nui o ka puʻuwai, a ʻo ko lākou pōʻino a me ka make kekahi o nā kumu nui o nā maʻi cardiovascular. Hiki i ka FOXO4-DRI ke hoʻoikaika i ka protein FOXO4, hoʻonui i ka hōʻike o nā enzyme antioxidant, e hoʻemi i ke kiʻekiʻe o nā ʻano oxygen reactive intracellular i loko o nā cardiomyocytes, a hoʻēmi i ka pōʻino o ke koʻikoʻi oxidative i nā cardiomyocytes. I ka manawa like, hiki i ka FOXO4-DRI ke hoʻoikaika i ka hōʻike ʻana o nā protein anti-apoptotic, kaohi i ka hoʻāla ʻana o ke ala hōʻailona apoptotic, a pale i nā cardiomyocytes mai apoptosis [4].
Ke hoʻoikaika nei i ka hana o nā pūnaewele Endothelial Vascular:
Hiki i ka FOXO4-DRI ke hoʻoikaika i ka hana maʻamau o nā pūnaewele endothelial vascular a mālama i ka paʻa a me ka elasticity o nā kīʻaha koko. ʻO nā ʻāpana endothelial vascular kahi ʻāpana koʻikoʻi o ka pā kīʻaha koko, a ʻo kā lākou hana maʻamau e alakaʻi i ka hiki ʻana o nā maʻi cardiovascular e like me ka piʻi ʻana o ka vascular permeability, thrombosis, a me atherosclerosis. Hiki i ka FOXO4-DRI ke ho'āla i ka protein FOXO4, hoʻoponopono i ka hōʻikeʻana o nā genes he nui i loko o nā pūnaewele endothelial vascular, hoʻoikaika i ka hoʻonui, ka neʻeʻana, a me ka hoʻoponoponoʻana i nā pūnaewele endothelial vascular, a mālama i ka hana maʻamau o nā kīʻaha koko. Eia kekahi laʻana, hiki i ka FOXO4-DRI ke hoʻonui i ka hōʻikeʻana o ka mea ulu ulu o ka endothelial vascular (VEGF), e hoʻonui i ka hoʻonuiʻana o nā pūnaewele endothelial vascular a me ka angiogenesis; Hiki iā ia ke hoʻonui i ka ʻōlelo o ka endothelial nitric oxide synthase (eNOS), hoʻoikaika i ka hana ʻana o ka nitric oxide, hoʻomāhuahua i nā kīʻaha koko, a hoʻemi i ke koko [4].
Ka pale ʻana a me ka mālama ʻana i nā maʻi cardiovascular:
I ka hōʻuluʻulu ʻana, kōkua ʻo FOXO4-DRI i ka pale a mālama ʻana i nā maʻi cardiovascular e like me ka myocardial infarction, heart failure, and atherosclerosis. I loko o kahi hoʻohālike holoholona o ka myocardial infarction, hiki i ka mālama ʻana me FOXO4-DRI ke hōʻemi i ka make ʻana o nā cardiomyocytes, hoʻoikaika i ka hoʻoponopono ʻana i ka ʻiʻo myocardial, a hoʻomaikaʻi i ka hana naʻau. I loko o kahi hoʻohālike puʻuwai, hiki i ka FOXO4-DRI ke kāohi i ka apoptosis o nā cardiomyocytes, hoʻonui i ka contractility myocardial, a hoʻomaikaʻi i ka hana pumping o ka puʻuwai. I loko o kahi hoʻohālike atherosclerosis, hiki i ka FOXO4-DRI ke hoʻemi i ka pōʻino o nā pūnaewele endothelial vascular, kaohi i ka pane inflammatory, a hoʻemi i ka hopena o ka atherosclerosis [4].
I ka hopena, ma o kāna mau hana o ka hana, me ka hoʻoulu ʻana i ka apoptosis o nā senescent cell, hoʻomaikaʻi i ka microenvironment tissue, a me ka hoʻopaneʻe ʻana i ke kaʻina hana ʻelemakule, FOXO4-DRI hōʻike i ka waiwai noi kūpono i nā kula o ka anti-aging, ka mālama ʻana i ka hypofunction testicular, radiation-induced pulmonary fibrosis, nā maʻi neurodegenerative, a me ka pale ʻana a me ka mālama ʻana i nā maʻi cardiovascular.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He mea noiʻi ʻo Han X i pili me nā ʻoihana kaulana he nui, e like me ka Jiangxi Academy of Science, Fudan University, Hunan University, Zhengzhou University, University of Geosciences, Sichuan University, National University of Singapore, Ministry of Natural Resources of the People's Republic of , Chinese Academy of Medical Science - Peking Union Medical College, Peking Union Medical College, Jiang Xi Acad Medical University, To Guilan University Medical College, Jiang Xi Acad Medical University Ke Kula Nui Hikina Akau - . Hōʻike kēia mau pili i kona ʻano hoʻonaʻauao ākea a ʻokoʻa.
ʻO kāna mau noiʻi noiʻi e pili ana i nā ʻāpana kumuhana koʻikoʻi. Ke hana ikaika nei ʻo ia i ka noiʻi i loko o nā kahua o ka Chemistry, Environmental Science & Ecology, Research & Experimental Medicine, Oncology, a me Biochemistry & Molecular Biology. Hōʻike kāna hana i ka ʻike ākea a me nā haʻawina nui i kēia mau wahi. Hoʻopaʻa ʻia ʻo Han X ma ka ʻōlelo kuhikuhi [2].
▎ Nā ʻōlelo pili
[1] Zhang C, Xie Y, Chen H, et al. Hoʻopau ʻo FOXO4-DRI i ka lawa ʻole o ka testosterone huna e pili ana i ka makahiki ma o ka huli ʻana i nā cell senescent Leydig i nā ʻiole kahiko [J]. ʻO ka ʻelemakule (Albany Ny), 2020,12(2):1272-1284.DOI:10.18632/ʻelemakule.102682.
[2] Han X, Yuan T, Zhang J, a me al. ʻO ka FOXO4 peptide e hoʻopaʻa i ka myofibroblast e hoʻomaikaʻi i ka bleomycin-induced pulmonary fibrosis i nā ʻiole ma o ka ECM-receptor interaction pathway [J]. Nūpepa o ka Cellular and Molecular Medicine, 2022,26(11):3269-3280.DOI:10.1111/jcmm.17333.
[3] ʻO Theoharides TC, Tsilioni I. Tetramethoxyluteolin no ka mālama ʻana i nā maʻi neurodegenerative [J]. Nā kumuhana o kēia manawa i ka lāʻau kemika, 2018,18(21):1872-1882.DOI:10.2174/ 15680266176 66 18111915424 7.
[4] ʻO Aslam DI, Jiyanboyevich Y, Ergashboevna A. Kāohi a me ka mālama ʻana i nā maʻi cardiovascular [J]. The American Journal of Medical Sciences and Pharmaceutical Research, 2021,03:180-188.DOI:10.37547/TAJMSPR/Volume03Issue06-28.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a maʻi paha. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.